HEALTHCARE · NSE/BSE: MANKIND

Mankind Pharma Limited Earnings Summary — Q1 FY2027

Sentiment: Positive

AI-generated summary

Generated 2026-10-22

Business Intelligence Report

Mankind Pharma Limited Q1 FY2027 results: Profit up +29.6% YoY; revenue grew +12.9% YoY; OPM 26.2%.

Quarterly Business Intelligence

Q1 FY2027

Financials from Financial Intelligence · data as of 2026-06-30

Revenue

₹4,031 Cr

QoQ +17.1%YoY +12.9%

Net Profit

₹568 Cr

QoQ +2.5%YoY +29.6%

Operating Profit

₹1,056 Cr

QoQ +13.6%YoY +24.7%

Operating Margin

26.2%

QoQ -81 bpsYoY +248 bps

AI Quarterly Scorecard™

/ 100

Strong

Revenue Momentum93

Profit Growth75

Margin Expansion73

Growth Consistency75

Operating Efficiency71

Financial Stability71

Computed deterministically from the last 10 reported quarters.

Quarterly Business Momentum

Revenue & Growth

Revenue grew 17.1% sequentially in Q1 FY2027.
Revenue of ₹4,031 Cr is 12.9% higher year-on-year.
Revenue has compounded at 25.4% annualised over the last 10 quarters.
Revenue is at its highest level in 10 quarters.

Profitability

Net profit of ₹568 Cr is 29.6% above the same quarter last year.
Profit growth is outpacing revenue growth, pointing to positive operating leverage.
Net profit has compounded at 8.7% annualised across the period.

Margins

Operating margin stands at 26.2% in Q1 FY2027.
Operating margin expanded by 248 bps year-on-year.
Over the last two years operating margin has expanded by 278 bps.
PBT margin is 19.1%.

Operating Efficiency

Expense growth of 9.2% remained below revenue growth of 12.9%.
Operating profit of ₹1,056 Cr is 24.7% higher year-on-year.
Operating leverage continues to improve.

Overall Momentum

6 of the last 6 measured quarters delivered year-on-year revenue growth.
Overall quarterly business momentum scores 76/100 (Strong) on the latest 10 quarters.
Business momentum remains positive heading into the next quarter.

Quarterly Financials

Last 10 Reported Quarters • All figures in ₹ Crore • Margins in %

Metric	Trend	Latest Q1 FY2027	Q4 FY2026	Q3 FY2026	Q2 FY2026	Q1 FY2026	Q4 FY2025	Q3 FY2025	Q2 FY2025	Q1 FY2025	Q4 FY2024
Revenue	Improving	4,031	3,443	3,567	3,697	3,570	3,079	3,199	3,061	2,868	2,422
Expenses	Improving	2,974	2,513	2,648	2,776	2,724	2,396	2,383	2,214	2,196	1,836
Operating Profit	Improving	1,056	930	919	921	847	683	816	847	672	586
Operating Margin	Stable	26.2%	27.0%	25.8%	24.9%	23.7%	22.2%	25.5%	27.7%	23.4%	24.2%
Other Income	Volatile	49	94	-31	94	83	249	87	109	108	94
Interest	Volatile	110	142	157	170	171	191	221	7	11	9
Depreciation	Strong Uptrend	226	223	223	222	219	231	187	100	103	100
Profit Before Tax	Improving	769	659	509	624	540	511	495	849	666	572
Tax	Accelerating	195	100	95	104	96	86	110	190	123	95
Net Profit	Improving	568	554	409	512	438	421	380	653	536	471
Net Margin	Stable	14.1%	16.1%	11.5%	13.8%	12.3%	13.7%	11.9%	21.4%	18.7%	19.4%

Source: Financial Intelligence (Structured Quarterly Data)•Latest Quarter: Q1 FY2027•Figures in ₹ Crore • Margins in %•Automatically updated from Financial Intelligence · 2026-06-30

Key Takeaways

Profit up +29.6% YoY; revenue grew +12.9% YoY; OPM 26.2%.

Official Quarterly Documents

Earnings Press Release

Official quarterly earnings release published by the company.

Press Release not available.

Earnings Call Transcript

Management discussion and analyst Q&A.

This summary is AI-generated from Mankind Pharma Limited's latest quarterly filing and earnings call. For informational purposes only — not investment advice.